SI-BONE Inc

SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 2008 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SI-BONE reports record Q4 revenue, eyes global growth opportunities

SI-BONE's Q4 2022 performance reflects robust revenue growth and operational improvements, driven by increased surgeon engagement and product adoption.
The company's financial stability, strong cash position, and strategic focus on growth opportunities position it well for future success and market expansion.
While facing challenges such as undisclosed study enrollment and international growth pacing, SI-BONE's focus on operational efficiency and market opportunities presents a positive outlook for sustained growth and profitability.

SI-BONE Inc reports robust Q1 revenue growth and raises 2023 guidance

SI-BONE Inc had a strong Q1 performance with robust revenue growth and surgeon adoption. While facing some challenges with expense increases, the company is optimistic about future growth opportunities and aims for improved financial performance throughout 2023.

SI-BONE Inc reports robust Q2 growth and optimistic outlook

SI-BONE Inc's Q2 2023 showcased strong revenue growth, improved operational efficiency, and enhanced cash position.
Company's product portfolio, FDA clearances, and revenue guidance revisions underscore its growth potential and market competitiveness.
Challenges include managing increased operating expenses, evolving marketing strategies, and maintaining growth momentum.
Opportunities lie in expanding surgeon base, leveraging training programs, conducting market studies, and aiming for a strong second half performance.

SI-BONE reports record revenue in Q3 2023, eyes market expansion

SI-BONE's Q3 2023 earnings call showcased robust financial performance, strong market positioning, and growth prospects. With record revenue, increased guidance, and a focus on innovation and market expansion, SI-BONE is well-positioned for continued success in the medical device industry.

SI-BONE reports record revenue growth and strategic product launches

SI-BONE Inc delivered strong financial performance in Q4 2023, with record revenue, improved EBITDA, and a solid cash position for future growth initiatives.
The company's strategic strengths lie in its U.S. market dominance, innovative product launches, and positive revenue guidance for 2024.
Challenges include expanding international revenue, pricing competitiveness, and effective training for new products, while opportunities exist in market expansion and product innovation.
Overall, SI-BONE's performance highlights its resilience, growth potential, and strategic focus on driving innovation and market expansion in the medical device sector.

SI-BONE Inc reports robust Q1 revenue growth and strategic focus

SI-BONE Inc's Q1 performance reflects strong revenue growth and operational achievements, underpinned by strategic priorities and market differentiation. While facing challenges in expense management and profitability, the company is well-positioned to capitalize on opportunities through innovation and market disruption.

SI-BONE Inc reports strong Q2 earnings, eyes growth opportunities

SI-BONE Inc delivered robust financial performance in Q2 2024, driven by revenue growth, increased active physicians, and improved EBITDA.
The company's strengths lie in customer loyalty, innovation, leadership enhancements, and a clear path to financial sustainability.
Challenges include operational scalability, sustaining revenue growth, balancing innovation with cost control, and effective Board integration.
Opportunities for SI-BONE include accelerating revenue growth, expanding into new market segments, diversifying product offerings, and leveraging strategic Board additions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA.

Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

SANTA CLARA, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 BofA Securities Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 14, at 2:20 p.m. Eastern Time / 11:20 a.m. Pacific Time.

SI-BONE To Present at BofA Securities 2024 Healthcare Conference on May 14, 2024

SANTA CLARA, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy today announced it will report financial results for the first quarter of 2024 after market close on Monday, May 6, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SI-BONE To Report First Quarter 2024 Financial Results on May 6, 2024

SANTA CLARA, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Barclays 26th Annual Global Healthcare Conference in Miami. Management will be hosting a fireside chat on Tuesday, March 12, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.

SI-BONE to Present at Barclays 26th Annual Global Healthcare Conference on March 12, 2024

SANTA CLARA, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023.

SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance

Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

SANTA CLARA, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter and full year ended December 31, 2023 after market close on Monday, February 26, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SI-BONE To Report Fourth-Quarter and Full-Year 2023 Financial Results on February 26, 2024

SANTA CLARA, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announces FDA 510(k) premarket clearance of the iFuse Bedrock Granite® Implant System (Granite) in a smaller (9.5 mm) diameter with both an expanded indication in pediatric patients and an expanded application that includes use in the S1 trajectory. When placed across the SI joint, the Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for multi-segment spinal fusion.

SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application

Fiscal Year 2023 revenue of $138.5 - $138.7 million representing growth of over 30% Fiscal Year 2023 revenue of $138.5 - $138.7 million representing growth of over 30%

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2023

Si-Bone (SIBN) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, SIBN broke out above the 50-day moving average, suggesting a short-term bullish trend.

Si-Bone (SIBN) Crossed Above the 50-Day Moving Average: What That Means for Investors

Today, we take a look at SI-BONE, Inc., a medical device company focused on developing implantable devices for musculoskeletal disorders. The company is targeting a large potential market, delivers consistent sales growth, and has a solid balance sheet. However, SI-BONE is some years away from profitability and the shares have seen some considerable insider selling in 2023.

Sizing Up SI-BONE After Q3 Earnings

SANTA CLARA, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Tuesday, November 28, 2023, at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time.

SI-BONE To Present at Piper Sandler 35th Annual Healthcare Conference on November 28, 2023

SI-BONE, Inc. (NASDAQ:SIBN ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of IR Laura Francis - CEO Anshul Maheshwari - CFO Conference Call Participants Young Li - Jefferies Drew Ranieri - Morgan Stanley Craig Bijou - Bank of America David Saxon - Needham & Company Dave Turkaly - JMP Securities Caitlin Cronin - Canaccord Samuel Brodovsky - Truist Securities Operator Good afternoon and welcome to SI-BONE's Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

SI-BONE, Inc. (SIBN) Q3 2023 Earnings Call Transcript

Annual guidance increased to $136 million - $137 million, implying annual growth of 28%-29% Annual guidance increased to $136 million - $137 million, implying annual growth of 28%-29%

SI-BONE, Inc. Reports Record Financial Results for the Third Quarter 2023 and Raises Annual Guidance

SANTA CLARA, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Jefferies London Healthcare Conference in London, UK. Management will be hosting a fireside chat on Wednesday, November 15, 2023, at 4:00 a.m. Eastern Time / 1:00 a.m. Pacific Time.

SI-BONE To Present at Jefferies London Healthcare Conference on November 15, 2023

SANTA CLARA, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2023 after market close on Monday, November 6, 2023. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SI-BONE to Report Third Quarter 2023 Financial Results on November 6, 2023

Si-Bone (SIBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Si-Bone (SIBN) Upgraded to Buy: Here's Why

Here is how Si-Bone (SIBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.

Has SiBone (SIBN) Outpaced Other Medical Stocks This Year?

The consensus price target hints at a 39.9% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Si-Bone (SIBN) Have the Potential to Rally 39.93% as Wall Street Analysts Expect?

SANTA CLARA, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company focused on sacropelvic surgical solutions, today confirmed that certain CD Horizon® Solera® 5.5mm and 6.0mm posterior spinal fixation rods manufactured by Medtronic Sofamor Danek USA Inc., a division of Medtronic plc, meet SI-BONE's criteria for compatibility with iFuse Bedrock Granite® indicated in the Granite implant's instructions for use. A complete list of Medtronic Solera® rods meeting the criteria for compatibility described in Granite's cleared labeling is available on SI-BONE's website at: http://www.si-bone.com/granite-implant-solera-compatbibility-criteria.

SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera® 5.5/6.0 System Rods

SI-BONE, Inc. presents compelling long-term value with robust growth in unit economics, high gross profits, and attractive valuation upside. Q2 FY'23 showed record-breaking sales of $33.3 million, with 31% growth in the U.S. market and 5th consecutive quarter of record revenues. The company's capital allocation and recycling strategies, along with positive sentiment and valuation, support a buy rating.

SI-BONE: Another Record Quarter, Reinvesting For Future Growth, Reiterate Buy

SANTA CLARA, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York. Management will be hosting a fireside chat on Tuesday, September 12, 2023, at 9:30 a.m. Eastern Time / 6:30 a.m. Pacific Time.

SI-BONE To Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023

SI-BONE, Inc. (NASDAQ:SIBN ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Saqib Iqbal - Senior Director, FP&A and Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Young Li - Jeffries Kyle Rose - Canaccord Samuel Brodovsky - Truist Securities Andrew Ranieri - Morgan Stanley Operator Good afternoon, and welcome to SI-BONE's Second Quarter Earnings Conference Call. At this time, all participants are in listen-only mode.

SI-BONE, Inc. (SIBN) Q2 2023 Earnings Call Transcript

Annual guidance increased to $132 million - $134 million, implying annual growth of 24%-26% Annual guidance increased to $132 million - $134 million, implying annual growth of 24%-26%

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2023 and Increases Annual Guidance

SANTA CLARA, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2023 Canaccord Genuity 43rd Annual Growth Conference in Boston. Management will be hosting a fireside chat on Wednesday, August 9th, 2023, at 12:00 p.m. Eastern Time / 9:00 a.m. Pacific Time.

News for SI-BONE Inc Stock (SIBN)